Trial Profile
Pilot Study of Gemcitabine and Cisplatin Plus AGS-003-BLD in Patients With Muscle-Invasive Bladder Cancer Undergoing Neoadjuvant Cisplatin-Based Chemotherapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Rocapuldencel T (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 14 Nov 2017 Planned primary completion date changed from 1 Nov 2021 to 5 Sep 2017.
- 14 Nov 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Oct 2016 New trial record